STOCK TITAN

Cytokinetics Inc - CYTK STOCK NEWS

Welcome to our dedicated page for Cytokinetics news (Ticker: CYTK), a resource for investors and traders seeking the latest updates and insights on Cytokinetics stock.

Cytokinetics Inc (NASDAQ: CYTK) is a biopharmaceutical leader pioneering muscle-targeted therapies for cardiovascular and neuromuscular diseases. This dedicated news hub provides investors and researchers with timely updates on the company's clinical developments, regulatory milestones, and strategic initiatives.

Access consolidated information on clinical trial progress, FDA communications, and research partnerships critical to understanding Cytokinetics' position in muscle biology therapeutics. Our repository ensures efficient tracking of earnings reports, intellectual property updates, and scientific advancements related to their small molecule drug candidates.

Bookmark this page for streamlined monitoring of Cytokinetics' innovations in cardiac muscle activators and neuromuscular treatments. Regular updates provide essential insights into the company's progress addressing conditions like heart failure and ALS through novel therapeutic approaches.

Rhea-AI Summary

Cytokinetics (NASDAQ: CYTK) has appointed Robert E. Landry to its Board of Directors, bringing over three decades of pharmaceutical industry financial and operational expertise. Landry most recently served as Chief Financial Officer at Regeneron Pharmaceuticals for 11 years, where he managed financial operations, investor relations, IT, competitive intelligence, and global facilities.

During his tenure at Regeneron, Landry oversaw two public acquisitions (Checkmate Pharmaceuticals and Decibel Therapeutics) and helped establish global affiliates as the company experienced substantial market capitalization and workforce growth. Previously, he spent 25 years at Wyeth and Pfizer in various roles including Corporate Treasurer and CFO of Wyeth Australia and New Zealand.

The appointment comes as Cytokinetics approaches potential approval and launch of its first medicine, with the company aiming to become a fully integrated organization focused on sustainable growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
management
-
Rhea-AI Summary

Cytokinetics (Nasdaq: CYTK) has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's President and Chief Executive Officer, Robert I. Blum, will engage in a virtual fireside chat scheduled for Wednesday, February 12, 2025, at 4:40 PM Eastern Time.

Interested participants can access the live webcast through the Investors & Media section of Cytokinetics' website. Following the event, the webcast recording will remain accessible on the company's website for a 90-day period.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.41%
Tags
conferences
-
Rhea-AI Summary

Cytokinetics (CYTK) has announced inducement grants to 13 new employees who joined in January 2025. The grants include:

- 64,587 stock options at $49.46 per share (closing price on January 31, 2025), vesting over 4 years with a 10-year term
- 41,939 restricted stock units (RSUs) vesting over 3 years (40% in year 1, 40% in year 2, 20% in year 3)
- 6,066 performance stock units (PSUs) tied to two performance goals

The PSUs will be earned based on achievement of two performance goals, with 50% of earned shares vesting upon Committee certification and the remaining 50% one year later. All grants were made under Nasdaq Listing Rule 5635(c)(4) as material inducements to employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
none
Rhea-AI Summary

Cytokinetics (NASDAQ: CYTK) has announced the recipients of its seventh annual Communications Grant Program, awarding a total of $100,000 to five patient advocacy organizations focused on hypertrophic cardiomyopathy (HCM) and heart failure communities. Each organization received $20,000 to support communications, awareness building, and community engagement initiatives.

The 2025 grant recipients include AICARM APS (Italian Association of Cardiomyopathies), HeartBrothers Foundation, HeartCharged , Hypertrophic Cardiomyopathy Association (HCMA), and Stichting Cardiomyopathie Onderzoek Nederland. The funds will support various projects including educational video production, patient quality of life assessments, short films about HCM patient experiences, digital partnerships, and qualitative research to improve patient and healthcare professional engagement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.71%
Tags
none
-
Rhea-AI Summary

Cytokinetics (CYTK) has initiated AMBER-HFpEF, a Phase 2 clinical trial for CK-586 in patients with symptomatic heart failure with preserved ejection fraction (HFpEF). The study is designed as a randomized, placebo-controlled, double-blind, multi-center, dose-finding trial, specifically targeting patients with LVEF ≥60%.

CK-586, a cardiac myosin inhibitor, is being developed to treat a subgroup of HFpEF patients with hypercontractility and ventricular hypertrophy. The trial's focus on HFpEF patients is significant as approximately half of heart failure patients have this condition, characterized by ejection fraction ≥50%, impaired diastolic function, and elevated NTpro-BNP.

The development strategy builds on similarities between a subset of HFpEF patients and those with non-obstructive hypertrophic cardiomyopathy (nHCM), leveraging data from aficamten in nHCM.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
-
Rhea-AI Summary

Cytokinetics (CYTK) has announced its 2025 milestones and Vision 2030 strategic plan. The company anticipates a PDUFA target action date of September 26, 2025 for aficamten, its cardiac myosin inhibitor for obstructive HCM. Key 2025 milestones include preparing for aficamten's U.S. commercial launch in 2H 2025, expanding European commercial readiness for potential EMA approval in 1H 2026, and supporting potential approval in China in 2H 2025.

The company will report topline results from MAPLE-HCM Phase 3 trial in 1H 2025, complete enrollment for ACACIA-HCM Phase 3 trial and CEDAR-HCM pediatric trial in 2H 2025. Additionally, Cytokinetics continues patient enrollment in COMET-HF for omecamtiv mecarbil and plans to complete enrollment of initial cohorts in AMBER-HFpEF for CK-586.

Vision 2030 objectives include advancing two approved products across three indications, developing ten novel molecular entities, reaching over 100,000 patients globally, and expanding access to medicines in more than 15 countries throughout North America and Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
none
Rhea-AI Summary

Cytokinetics (CYTK) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's President and CEO, Robert I. Blum, will deliver a presentation on Monday, January 13, 2025, at 9:00 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco.

Interested investors and stakeholders can access the presentation through a live webcast available on the Investors & Media section of the Cytokinetics website. The recording will remain accessible on the company's website for 90 days following the event's conclusion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
conferences
-
Rhea-AI Summary

Cytokinetics (CYTK) has announced inducement grants to 9 new employees who joined in December 2024. The grants include:

- 52,188 stock options at $47.04 per share (closing price on Dec 31, 2024), vesting over 4 years with 1/4th after first year and 1/48th monthly thereafter

- 33,885 restricted stock units (RSUs) vesting over 3 years (40% after year 1, 40% after year 2, 20% after year 3)

- 3,189 performance stock units (PSUs) tied to two performance goals, with 50% of earned shares vesting upon goal certification and 50% one year later

All grants were made under Nasdaq Listing Rule 5635(c)(4) as material inducements to employment, subject to continued service requirements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
none
-
Rhea-AI Summary

Cytokinetics (CYTK) announced that the European Medicines Agency (EMA) has validated their Marketing Authorization Application (MAA) for aficamten, a cardiac myosin inhibitor designed to treat obstructive hypertrophic cardiomyopathy (HCM). The application will be reviewed by the Committee for Medicinal Products for Human Use (CHMP).

The MAA is supported by results from the SEQUOIA-HCM Phase 3 clinical trial, published in the New England Journal of Medicine. This follows the FDA's acceptance of aficamten's New Drug Application (NDA) in the US, which has a PDUFA target action date of September 26, 2025. The drug is also under regulatory review in China.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
none
Rhea-AI Summary

Cytokinetics (CYTK) has granted equity-based compensation to 7 new employees who joined in November 2024. The package includes 34,515 stock options at an exercise price of $51.86 per share and 22,410 restricted stock units (RSUs).

The RSUs will vest over 3 years: 40% after year one, 40% after year two, and 20% after year three. The stock options will vest over 4 years: 25% after the first year, with the remaining vesting monthly over 36 months. The options have a 10-year term. These grants were made as employment inducements under Nasdaq Rule 5635(c)(4).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
none
Cytokinetics Inc

Nasdaq:CYTK

CYTK Rankings

CYTK Stock Data

4.78B
115.78M
0.45%
114.77%
11.88%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO